Skip to main content
. 2019 Jan 10;8(1):69. doi: 10.3390/jcm8010069

Table 1.

Frequently used medication in COPD and cardiovascular disease.

Medication Indication Comment References
COPD steroids inhaled long-term therapy # good safety profile [57]
systemic exacerbation pro-arrhythmic potential [58]
beta agonists short acting exacerbation long-term therapy pro-arrhythmic potential (high doses) [50,51,52,59]
long acting long-term therapy acceptable safety profile
muscarinic antagonists short acting exacerbation long-term therapy pro-arrhythmic potential (high doses) [50,52,60]
long acting long-term therapy acceptable safety profile
PDE inhibitors Roflumilast long-term therapy reduction of cardiovascular events [12]
Theophylline (long-term therapy) narrow therapeutic range and considerable pro-arrhythmic potential [57,61]
Cardiovascular Disease beta blockers selective heart failure, CHD, ACS, AHT, SVT, VT often withheld or under dosed, prefer selective substances, overall good safety profile [40,41]
non-selective
antiplatelet therapy CHD, ACS dyspnea caused by reversible P2Y₁₂-antagonists (Ticagrelor, Cangrelor) [47]
Ivabradine CHD, heart failure alternative to beta blockers for anti-anginal and frequency control (sinus rhythm only) [42,62]
statins CHD, dyslipidemia secondary prevention, pleiotropic effects of immune system and inflammation [14,15]
ACE inhibitors AHT, heart failure no bronchoconstriction [45,46]
angiotensin receptor blockers alternative (ACE inhibitor induced cough)
calcium channel blockers AHT, CHD, SVT alternative to beta blockers for anti-anginal and frequency control, smooth muscle relaxation (small clinical effect) [42]
nitrates CHD alternative to beta blockers for anti-anginal control [42]
amiodarone SVT, VT pulmonary toxicity [63]

COPD: chronic obstructive pulmonary disease, PDE: phosphodiesterase, ACS: acute coronary syndrome, AHT: arterial hypertension, SVT: supraventricular tachyarrhythmia, VT: ventricular supraventricular, CHD: coronary heart disease, ACE: angiotensin converting enzyme. # in selected patients with frequent exacerbations or blood eosinophilia (see text for details).